Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Eleven new drugs added to the Dosage and Frequency Program

November 15, 2019

As of January 3, 2020, the Independence Dosage and Frequency Program will expand to include 11 new drugs. Most of these medical benefit drugs are used to treat pulmonary arterial hypertension or are biosimilars to antineoplastic agents that are already part of this program.

The following is the list of new drugs that will be added to this program:

  • Flolan® (epoprostenol sodium)
  • KanjintiTM (trastuzumab-anns)
  • Krystexxa® (pegloticase)
  • Remodulin® (treprostinil)
  • Revatio® (sildenafil)
  • RuxienceTM (rituximab-pvvr)
  • Tyvaso® (treprostinil)
  • Veletri® (epoprostenol)
  • Ventavis® (iloprost)
  • Xembify® (immune globulin subcutaneous, human-klhw)
  • ZirabevTM (bevacizumab-bvzr)

Learn more

For more information on the dosage and frequency guidelines, please refer to the medical policies for each drug in the program. To access these policies, visit our Medical Policy Portal.

The complete list of all 71 drugs on this program can be found on our website.

If you have any questions about this program, please call the Independence Clinical Services department at
1-800-ASK-BLUE (1-800-275-2583).

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.